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Abstract
Purpose This study aims to describe surgical management
results and the pathologic features of choroidal neovasculariza-
tion (CNV) secondary to punctate inner choroidopathy (PIC)
following anti-vascular endothelial growth factor treatment.
Design This study is a case report on the surgical management
and ultrastructural study of choroidal neovascularization.
Methods Clinicopathologic and ultrastructural report of
CNV membranes excised from both eyes of one patient
was presented.
Results The right eye responded to bevacizumab, and
recurrence 17 months later did not; the left eye never
responded. Excision of the active CNVs was performed
3 months after the last injection. In the right eye, there was
no recurrence 23 months after surgery. In the left eye, CNV
recurred after 6 months, with no response to bevacizumab.
Electron microscopy revealed subretinal neovascular tissue
and, additionally, Bruch's membrane and inner choroid in
the left. In the right eye, lumens of many neovascular
channels were occluded by microfibrils and pericytes were
infrequent. In the left eye, patent CNV units with pericytes
were present. There were scattered macrophages but no
lymphocytes in either membrane. An inner focal choroidal
lymphocytic infiltrate was discovered.
Conclusions Submacular surgery did not cause complica-
tions following treatment with bevacizumab. Mostly non-
functional capillaries in the right membrane failed to
display pericytes. The left membrane, which was unrespon-
sive to bevacizumab, displayed well-formed neovascular
units consistently exhibiting pericytes. A focus of inner
choroidal lymphocytic infiltration was found in the left eye
despite the absence of overt clinical intraocular inflamma-
tion. This is the first pathological study employing human
tissue that points to pericytes as a potential critical
therapeutic target with the aggravating influence of inner
choroidal chronic inflammation in PIC.
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Introduction
Punctate inner choroidopathy (PIC) is an idiopathic
disorder representing one point on a spectrum of the
multifocal choroiditides. The anterior segment and vitreous
are typically free of inflammation. The visual outcome is
good unless complicated by submacular choroidal neo-
vascularization (CNV), which may occur bilaterally. Treat-
ment options of CNV in PIC include argon laser
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photocoagulation, local or systemic corticosteroids or other
immunosuppressant agents, intravitreal anti-VEGF agents,
photodynamic therapy (PDT), and submacular surgery. In
CNV cases with subfoveal involvement, argon laser
photocoagulation has been associated with poor visual
outcome. Before the introduction of anti-vascular endothe-
lial growth factor (VEGF) agents, surgical excision was the
therapeutic option of last resort and only employed after
conventional management with corticosteroids or PDT had
failed.
Various angiogenic factors have been implicated in the
pathogenesis of CNV, with VEGF putatively the key player.
The advent of targeted pharmacologic inhibition of VEGF
has been a major advance in the management of CNV
secondary to age-related macular degeneration (AMD) [1].
There are no randomized clinical trials providing evidence
for the efficacy of intravitreal anti-VEGF agents in the
treatment of CNV in conditions other than AMD. Never-
theless, given their excellent safety profile, these agents are
widely used in all subfoveal CNV cases regardless of
etiology, including PIC [2, 3]. It remains unclear why CNV
responds in different ways to anti-VEGF treatment. A
multifactorial etiology of ocular angiogenesis, including
inflammation and mediators other than VEGF, as well as
the different levels of vascular maturation of the neo-
vascular complex, has been proposed.
To date, there is no report of the surgical management
and ultrastructural study of CNV secondary to choroiditis
following intravitreal anti-VEGF treatment. We report
herein on the clinical outcome of bilateral surgical excisions
of CNV in a PIC case which failed anti-VEGF treatment.
Electron microscopic evaluation was performed on the
excised specimens in an attempt to elucidate the pathogen-
esis of the condition and the possible mechanisms of
treatment failure.
Informed consent for the research was obtained from
the patient. The study is in accordance with HIPAA
regulations.
Clinical findings
A 42-year-old white woman presented with metamorphop-
sia in the right eye. Past ocular, medical and family history
was unremarkable. Visual acuity was 20/125 in the right
and 20/20 in the left. The patient was diagnosed with CNV
associated with PIC. The CNV regressed following one
intravitreal bevacizumab injection with an improvement in
vision to 20/25. It recurred 17 months later with a decrease
in vision to 20/40, and a second injection was administered
with no response. The patient deferred further intraocular
injections and could not tolerate systemic immunosuppres-
sion. She presented to us for submacular surgery evalua-
tion. Visual acuity was 20/40 in the right eye and 20/20 in
the left. Anterior segment and vitreous examination showed
no inflammation. Dilated fundus examination revealed
small punctate yellowish chorioretinal lesions bilaterally
consistent with choroiditis (Fig. 1a). In the right eye,
fluorescein angiography disclosed a classic subretinal neo-
vascular membrane (Fig. 1b, c). Optical coherence tomog-
raphy (OCT) revealed that the lesion was associated with
adjacent intraretinal cystic spaces (Fig. 2a, top).
Surgical removal of the CNV 3 months after the second
injection led to improvement in vision to 20/20-1 with
resolution of metamorphopsia (Figs. 1d and 2b middle and
c bottom). There has been no recurrence at 23 months of
follow-up after surgery.
CNV developed in the left eye 2 years after failed
pharmacotherapy in the right eye. Vision was 20/20-2 with
severe symptoms of metamorphopsia. There was no
response to two injections of bevacizumab (Fig. 3a–c).
Surgical removal of CNV 3 months after the second
injection (Fig. 3d) led to resolution of metamorphopsia
and improvement of vision to 20/20 at a 3-month follow-
up. Six months following surgery, visual acuity decreased
to 20/63-2 secondary to recurrence. There was no
response to additional treatment with bevacizumab.
Patient elected for repeat submacular surgery. Vision
improved to 20/32 5 months postoperatively. Ultrastruc-
tural studies of that specimen were not performed.
Informed consent was obtained from the patient regard-
ing evaluating the surgical specimens obtained by light
and electron microscopy.
Light and electron microscopic findings
The specimens obtained were evaluated by light microsco-
py in 1-μm plastic sections stained with toluidine blue and
by transmission electron microscopic examination of
ultrathin sections prepared according to standard techniques
(a mixture of 2.5% glutaraldehyde and 2% formaldehyde
fixation buffered in 0.1 M cacodylate followed by 2%
osmium fixation in an aqueous solution).
The first specimen was obtained from the right eye
20 months after the introduction of anti-VEGF therapy,
3 months after the most recent intravitreal bevacizumab
injection. The light microscopic evaluation of epon sections
revealed a hypocellular membrane featuring multiple
widely separated capillaries in the midst of a fibrillar
matrix without apparent inflammatory cells (Fig. 4a).
Cellular processes of pigment-bearing cells were widely
distributed throughout the tissue. Some of the vessels
contained erythrocytes, which were not detected in the
extracellular space. At one edge of the membrane, a cluster
of pigment epithelial cells was observed.
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At the ultrastructural level, no photoreceptors or
other retinal elements were detected. Two types of
capillaries were discovered. The predominant one
contained occasional intraluminal erythrocytes but was
for the most part occluded with microfibrils (Fig. 4b).
The endothelial cells were attenuated and fragmented and
a pericytic mantle was absent. A degenerating elongated
pigment epithelial cell process was occasionally identi-
fied. The second less common type of capillary had a
well-defined pericytic layer; only one such capillary was
identified in the specimen (Fig. 4c). The surrounding
fibrillar matrix was loose and a single macrophage was
identified nearby. The pigment epithelial cell cluster
exhibited a peculiar fine clumping of the nuclear
chromatin and disruption of the plasmalemmas, presum-
ably degenerative phenomena, causing the extracellular
release of melanin granules.
The membranous tissue excised from the left eye 5 months
after initiation of therapy and 3 months after most recent
intravitreal injection comprised the inner choroid with its
choriocapillaris, Bruch’s membrane, and a vascularized
subretinal multilaminar cellular membrane with many
capillary-type units (Fig. 4d). In the epon-embedded, light
microscopic sections, no break was detected in Bruch’s
membrane that demonstrated a vascular channel connecting
the choriocapillaris with the subretinal neovascular units.
The retinal pigment epithelial (RPE) layer was disrupted and
disorganized. A prominent extracellular fibrillary matrix was
not observed and photoreceptor cells were not seen. The
inner choroid harbored a distinct focus of chronic inflam-
matory cells without follicular organization.
By transmission electron microscopy, the pigment
epithelium consisted of one or two layers at the center of
the membrane with neovascular channels distributed among
Fig. 1 Right eye. a Preoperative color photograph demonstrates
multiple, small, yellowish punctate lesions at the level of the choroid.
A subfoveal CNV membrane with hyperpigmented borders is seen. b
Early transit of the fluorescein angiogram shows early hyperfluor-
escence of the CNV lesion. c Late phase of the angiogram shows
leakage from the CNV along with multiple punctate hyperfluorescent
lesions in the peripapillary area and the periphery. d Fundus
photograph 1 month after surgical excision of CNV showing RPE
atrophy
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them in the absence of inflammation (Fig. 5a). One layer
of RPE was present toward the periphery of the mem-
brane. The RPE cells and neovascular channels in the
middle of the lesion also interfaced with broad processes
of Mueller cells without the interposition of photorecep-
tors or their degenerative remains (Fig. 5b). The Mueller
cells were characterized by multiform mitochondria,
abundant profiles of smooth surfaced endoplasmic reticu-
lum, and the absence of pigment granules. Poorly
pigmented displaced RPE cells contained rare pigment
granules, profiles of rough surfaced endoplasmic reticu-
lum and manifested segments of basement membrane
material and disorganized surface villi. Extravasated
erythrocytes, macrophages, lymphocytes, and conspicuous
extracellular matrix material were not found in the
membrane, except for the last which was limited to the
pericapillary zone. The viable neoformed intramembra-
nous capillaries displayed patent lumens with endothelial
cell fenestrae and uniformly enveloping pericytes, both
ensheathed by basement membranes (Fig. 5b).
At the edge of the membrane, a single layer of dyspolar
pigment epithelial cells without apical villi was surrounded
by whorled membranous bodies of various sizes, some of
which were engulfed by the RPE cells and others by
macrophages (Fig. 5c). These probably represented degen-
erative fragments of photoreceptor outer segments. The
subadjacent choriocapillaris was patent, nondamaged and
uninflamed. The focus of inner choroidal inflammatory
cells was composed of mature small lymphocytes with
clumped chromatin and scant cytoplasm without intermixed
histiocytes and plasma cells (Fig. 5d). The choroidal
melanocytes were focally damaged and had released their
Fig. 2 Right eye. a (Top) OCT before surgical excision of CNV showing hyperreflective area at the level of the RPE corresponding to the CNV. b
(Middle) OCT 3 months after surgical excision of CNV. c (Bottom) OCT 15 months after surgical excision of CNV
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small pigment granules extracellularly, which had attracted
melanophages (Fig. 5d).
Discussion
This report documents for the first time the healing
response following anti-VEGF treatment of CNVs and
highlights possible causes of treatment failure. We also
analyzed the clinical and anatomical implications of
surgical removal of CNVs following treatment failure of
anti-VEGF agents. There is one other report in the literature
of excision of a CNV membrane following intravitreal
injection of the anti-VEGF agent bevacizumab, in which
only avascular fibrous tissue was described pathologically
[4].
The submacular membranes removed from both eyes
in our case had significantly different light and electron
microscopic features. That from the right eye, which
had been followed and treated over a span of 20 months
prior to surgical excision (in comparison with 5 months
for the left eye), was remarkably hypocellular and
mainly composed of abundant fibrillocollagenous mate-
rial. Apart from the presence of rare elongated processes
of degenerating pigment epithelial cells or an occasional
macrophage, lymphocytes and plasma cells were absent.
A cluster of polygonal pigment epithelial cells at the
membrane’s base near Bruch’s membrane displayed
disrupted plasmalemmas and a disturbed nuclear chro-
matin pattern of fine clumping compatible with incipient
dissolution. The ability of the RPE cells to undergo
fibrous and even osseous metaplasia is well recognized
[5]. The vascular endothelial cells of the membrane’s
capillaries were attenuated and fragmented, and their lumens
were filled with microfibrils. Pericytes were overwhelmingly
absent. Only one capillary appeared functional with healthier
looking constituent cells that included fenestrated endothelial
cells andwell-preserved pericytes. In this zone, the surrounding
Fig. 3 Left eye. a Color fundus photograph 3 months after second
injection of bevacizumab shows a grayish subfoveal CNV membrane.
b Early phase of the fluorescein angiogram reveals hyperfluorescence
corresponding to the CNV lesion with hypofluorescent borders
corresponding to the pigmented borders of the lesion. c Late phase
of the angiogram reveals leakage of the CNV lesion. d Intraoperative
view of the excised CNV lesion
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extracellular matrix was looser, suggesting that such vessels
were of more recent origin than the others and probably
related to the recurrence.
In contrast, the submacular membrane that was removed
from the left eye 5 months after initiation of treatment
displayed virtually no extracellular fibrillar matrix material.
Instead it manifested blunted processes of Mueller cells in
apposition to RPE cells. The obviously viable and intact
vascular endothelial cells displayed fenestrae and were
consistently surrounded by pericytes. The fenestrae support
an origin of the neovascular units from the choriocapillaris,
which normally possesses this feature. The growth pattern
of the CNV was subretinal, in accordance with previous
reports [6]. There was no evidence of a lymphohistiocytic
inflammatory component accompanying the subretinal
neovascularization throughout most of the membrane, as
also described in a previous immunohistochemical study of
CNV in PIC [7]. Olsen et al., however, reported moderate
to prominent lymphocytic infiltration in four out of the six
CNV specimens studied [6].
The pigment epithelial cells in the left membrane remained
for the most part confined to one or two layers at the base of
the membrane and were in direct apposition to broad
processes of Mueller cells without the interposition of photo-
receptors or their degenerative remnants. The latter were
discovered at the borders of the membrane in the form of
whorled lamellated membranous bodies probably represent-
ing degenerative products of outer segments. This finding
suggests a primary degenerative mechanism rather than an
infarction, which would have produced a more complete and
broader effacement of cellular detail with a prominent
inflammatory cell infiltrate. Finally, the fortuitous discovery
of lymphocytes at the level of the inner choroid with sparing
of the choriocapillaris lends, for the fist time, ultrastructural
electron microscopic support to the hypothesis that PIC is an
inflammatory disease, with the inflammation originating in
Fig. 4 a Right submacular surgical specimen consists of collagen with
many capillary channels (arrows), some of which have erythrocytes in
their lumens (crossed arrows). Scattered pigment granules are observed,
with a concentration of pigment epithelial cells (PE) toward the bottom
left (Toluidine blue, ×200). b A nonfunctioning capillary exhibits
attenuation and fragmentation of the endothelial (EN) cell layer in the
absence of pericytes. Note the persistence of erythrocytes (ER) within
the lumen, which is filled with microfilaments (F). H histiocyte, PE
retinal pigment epithelial cell process, MA extracellular fibrocollagenous
matrix (EM ×2,600). c A viable neovascular unit displays endothelium
(E) with focal fenestrations (f) and elongated lumen (L). Both the
endothelial cells and surrounding pericytes (P) are clothed by a
basement membrane. The matrix (MA) is looser in this region and
contains a macrophage (M) with complex phagolysosomes (V) and
surface villi (vi). (EM ×5,800). d Multilaminar membrane (M) from the
left eye has formed above Bruch’s membrane (BM) and contains small
neovascular units (arrows). The adherent choriocapillaris (Cc) is patent.
Within the choroid (CH) is a small collection of lymphocytes (LY).
Inset: erythrocytes in a neovascular lumen (arrow). (Toluidine blue,
×200)
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the choroid. There are no other EM studies of tissue excised
from a PIC case that include choroid manifesting inflamma-
tory infiltration.
Thus, there was a striking difference in the response of
the two submacular membranes to bevacizumab treatment.
While different durations of the two membranes before
their removal created concomitant differences in the amount
of collagen deposition, the chief ultrastructural differential
feature was the pronounced regression of the neoformed
vessels in the right eye that lacked pericytes (in comparison
with those in the left eye that possessed them). This
phenomenon could be a primary feature of the neovascular
units themselves or reflect a preferential secondary loss during
the membrane’s evolution or treatment. The well-preserved
architecture of the endothelial-lined vascular channels with a
normal accompaniment of pericytes in the left eye intimates
that anti-VEGF treatment had no effect on them. The finding
of one capillary in the right specimen with fenestrated
endothelial cells and well-preserved pericytes, while all other
capillaries which were occluded manifested fragmented
endothelial cells and lacked pericytes, may signify that it
represented CNV nonresponsiveness to the most recent anti-
VEGF treatment 3 months prior to surgery. This is further
supported by the fact that in this zone the surrounding
extracellular matrix was looser, suggesting more recent origin
and less deposition of collagen as explained above. The
Fig. 5 a In the left eye, above Bruch’s membrane (BM) with its
elastic layer and subjacent choriocapillaris (CH), are two to three
layers of pigment epithelial cells (PE) with loss of polarity. A capillary
vessel (arrows) is present within the subretinal membrane. ME
choroidal melanocyte (EM ×1,450). b Pigment epithelial cells (PE)
approach a neovascular (NV) channel. The PE cells interface with
broad processes of Mueller cells (MC) in the upper half of the field
with myriad mitochondria. Inset: fenestrations (arrows) of the
endothelial cells of the neoformed capillary and a thick surrounding
basement membrane (BM) (EM ×1,950). c At the edge of the
membrane, pigment epithelial cells (PE) with basement membrane
(BM) are positioned on Bruch’s membrane (BM). Within the
cytoplasm of the central PE cell is a degenerated compact whorled
membranous body (arrow), another of which is also shown toward the
right in the cytoplasm of an indeterminate cell (crossed arrow). The
underlying choriocapillaris (Cc) with its endothelial cells (E) is patent.
CH choroid (EM ×2,600). d An inner choroidal inflammatory
infiltrate is composed of lymphocytes (L). Small uveal melanosomes
have been released into the extracellular space (arrows). A large
melanophage (M) contains complex phagolysosomes (crossed arrows)
of engulfed uveal melanin. E extravasated erythrocyte (EM ×1,450)
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capillaries with fragmented endothelial cells most likely
represent the regressed CNV treated with anti-VEGF agents
20 months prior to surgery.
Pericyte-poor neovascular units have been shown to be
more susceptible to anti-VEGF agents than pericyte-rich ones.
We therefore hypothesize that failure to respond to anti-VEGF
treatment in the left eye of our patient may be associated with
the uniform presence of a pericytic component in the
neovascular channels. VEGF expression in developing retinal
vasculature has been observed in pericytes contacting new
vessels [8]. These observations indicate that the presence of
pericytes may act as a survival factor for endothelial cells
and therefore increase resistance to anti-VEGF therapy.
Consequently, combination therapeutic strategies might be
applied to circumvent such nonresponsiveness. In this
context, dual VEGF and platelet-derived growth factor-
targeted therapy has been shown to be more effective in
inhibiting in vivo tumor growth than either agent alone [9].
Choroidal lymphocytic infiltration was found in the left
subretinal excision which included a segment of chorioca-
pillaris and surrounding inner choroidal tissue. A small
collection of lymphocytes was detected in the right eye.
This finding should not be totally unexpected despite the
absence of overt clinical intraocular inflammation. It
supports the concept that PIC is fundamentally an inflam-
matory condition. None of the eyes had undergone prior
surgery or photodynamic therapy that could have triggered
inflammation. The presence of a focus of choroidal
inflammation is also suggestive of the possibility that anti-
VEGF treatment of CNVs may fail because of underlying
persistent inflammation. This provides another basis for
considering a combination of therapeutic modalities in
addition to anti-VEGF factors to improve the efficacy of
treatment in CNVs secondary to PIC. This is the first report
showing persistent choroidal inflammation after anti-VEGF
treatment that could possibly provoke recurrent CNVs, in
contradistinction to inflammation in the membrane itself.
Available data on treatment of CNV associated to PIC
are derived from small nonrandomized case series. Local
and systemic treatment with steroids has not been proven
effective in the treatment of CNV associated with PIC, even
when administered at high doses for many months [6, 10].
Small retrospective series have suggested that PDT may be
effective [10]. More recent small prospective studies of
PDT in combination with either systemic steroids or 4 mg
intravitreal triamcinolone of five and four eyes, respectively,
showed decreased activity of CNV lesions [11, 12]. Larger
lesions though did not respond. Three out of the four patients
who received intravitreal triamcinolone experienced
improvement of two or more lines of vision and one patient
lost two or more lines at 1-year follow-up [12]. We should,
however, take into account the high rate of side effects of
systemic or local corticosteroid treatment.
Regarding the surgical management outcome of this
case, prior anti-VEGF treatment did not appear to compli-
cate surgical excision. In our series of three submacular
surgeries in two eyes, there were no adverse events peri- or
postoperatively, but the number is too small for any definite
conclusions. No recurrences occurred 23 months after
surgery in the right eye. CNV recurrence was noted
6 months postoperatively in the left eye. Repeat surgical
excision after failed anti-VEGF treatment was again
uneventful. This high rate of recurrence in our series is in
accord with the results of the Submacular Surgery Trial
(SST) trial in which recurrent CNV developed in 58% of
surgically treated eyes by the 24-month examination [13].
Recurrences occurred in four of six eyes with CNV
associated with PIC following surgical excision in the
series reported by Olsen et al. [6].
Following reports from the SST trial for CNV that
showed no benefit in preventing visual loss and a high rate
of adverse events, submacular surgery has been virtually
abandoned. SST reported on both type I membranes, which
grow below the RPE and are typically secondary to AMD,
and type II membranes, which grow subretinally. PIC is one
of the conditions, along with an idiopathic category,
myopia, and presumed ocular histoplasmosis syndrome,
that are complicated by type II CNVs. The SST trial
showed that surgical excision of CNV in POHS and
idiopathic cases probably has a more favorable visual
outcome in the subgroup of eyes with initial visual acuity
20/100 or worse [13]. A successful outcome was defined as
a visual acuity better, or no more than one line worse, than
at baseline. As a result, a smaller benefit of surgery, such as
reduction of risk of loss of three lines of vision, which
many trials have been designed to detect, could not be
confirmed. Also, 25% of patients were 60 years or older;
results may be more favorable in a younger cohort of
patients, as large case series have suggested [14]. Still,
submacular surgery carries significant risks and should be
considered only in selected cases nonresponsive or non-
tolerant to other treatment modalities.
In conclusion, this report provides evidence that inhibition
of VEGF alone cannot be relied upon to induce stable
and lasting regression of subretinal neovascularization in
PIC. A multimodal therapeutic approach may be
necessary to disrupt multiple signaling pathways in
neoangiogenesis. This is the first pathological study
employing human tissue that points to pericytes as a
potential critical target with the aggravating influence of
inner choroidal chronic inflammation.
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